## **International Society of Drug Bulletins**

## Form B: Disclosure of competing interests for bulletin staff

Unless a competing interest policy is part of the contract of employment, each staff member with responsibility for bulletin content should submit a declaration of competing interests each year. The chief editor or publisher of each bulletin is responsible for the collection of individual returns from staff members.

## **Section 1. Personal information**

Given Name (First Name) Jörg

Surname (Last Name) Schaaber

Date of completion of this form 1 October 2019

Role in the bulletin. Chief editor

Please specify whether your work for the bulletin is paid or unpaid: Paid

## Section 2. Relevant activities outside the bulletin

This section asks about your relationships with entities in the biomedical arena that could be perceived to influence your work for the bulletin. You should disclose interactions with **any** entity that could be considered broadly relevant to the work of the bulletin.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution (other than your bulletin) on your behalf over the past three years. This should include all monies from sources with relevance to, or an interest in, articles published in your bulletin.

For funds you have received for work outside your role with the bulletin, you should disclose support from entities, such as drug companies, public-private partnerships, or foundations supported by outside entities that could be perceived to benefit financially from your articles.

Public funding sources, such as government agencies, charitable foundations or political/academic institutions, need to be disclosed. For example, if a government agency sponsored a study in which you have been involved, or if you are involved in a project funded by a political/academic institution.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, your work for the bulletin? You are encouraged to err on the side of full disclosure. For example, voluntary participation in a government agency or academic institution working group may be relevant, especially if you have decision-making responsibilities in such a group.

Complete each row in this list by providing the requested information or answering "No". For each financial relationship, please specify in the space provided the entity, what the payment was for, and whether it was to you directly or to your institution.

- 1. Board membership No
- 2. Consultancy No
- 3. Employment No
- 4. Expert testimony No
- 5. Grants/grants pending No
- 6. Payment for lectures including service on speakers' bureaus No
- 7. Payment for manuscript preparation No
- 8. Patents (planned, pending or issued) No
- 9. Royalties No
- 10. Payment for development of educational presentations No
- 11. Shares and Stock (including options) No
- 12. Travel/accommodation/ meeting expenses unrelated to activities listed No
- 13. Other (please err on the side of full disclosure)

Since 2004 patient/consumer representative in the subcommittee for medicines of the German Federal Joint Committee (G-BA). Patient/consumer representatives have no voting rights. The G-BA decides about reimbursement for the statutory health insurance.